MedTrace Logo

Ticagrelor in Severe Community Acquired Pneumonia

NCT01998399 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2017-12-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if the drug ticagrelor will be an effective treatment for patients with severe community acquired pneumonia. The primary objective is to reduce all-cause mortality in the ticagrelor group compared to the placebo group.

Conditions

  • Community Acquired Pneumonia, Severe

Interventions

DRUG

Ticagrelor

Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days

DRUG

Placebo

Placebo 180 mg loading dose followed by 90 mg BID for 90 days.

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Gordon Bernard

    lead OTHER

Principal Investigators

  • Gordon R Bernard, MD · Vanderbilt University Medical Center

  • Jon D Truwit, MD · Medical College of Wisconsin

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01998399 on ClinicalTrials.gov